KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Work In Process (2018 - 2021)

BioNTech SE (BNTX) posted Work In Process of $96.7 million for Q4 2021, up 43.85% on a QoQ basis from $67.2 million in Q2 2021, and up 317.92% year-over-year from $23.1 million in Q4 2020.

BioNTech SE (BNTX) has 4 years of Work In Process data on file, last reported at $96.7 million in Q4 2021.

  • In Q4 2021, Work In Process rose 317.92% year-over-year to $96.7 million; the TTM figure through Dec 2021 stood at $96.7 million (up 317.92% YoY), while the FY2021 annual figure was $96.7 million, up 317.92% from the prior year.
  • Work In Process improved to $96.7 million in Q4 2021, from $67.2 million in the prior quarter.
  • Across five years, Work In Process topped out at $96.7 million in Q4 2021 and bottomed at $91311.7 in Q4 2018.
  • A 4-year average of $38.1 million and a median of $23.1 million in 2020 frame the typical range for Work In Process.
  • Annual changes were most pronounced in 2019 — Work In Process soared 3400.86% — and 2021, when it surged 317.92%.
  • Year by year, Work In Process stood at $91311.7 in 2018, then soared by 3400.86% to $3.2 million in 2019, then jumped by 623.57% to $23.1 million in 2020, then surged by 317.92% to $96.7 million in 2021.
  • The last three Work In Process figures came in at $96.7 million (Q4 2021), $67.2 million (Q2 2021), and $23.1 million (Q4 2020), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 BioNTech SE 27.66 Bn 7.53 Bn 668.28 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 96.67 Mn
Jun 30, 2021 67.20 Mn
Dec 31, 2020 23.13 Mn
Dec 31, 2019 3.20 Mn
Dec 31, 2018 91,311.71